Elixiron Immunotherapeutics Receives Grant from the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy

The Alzheimer’s Association today announced that we have been awarded a grant under their 2022 Part the Cloud program to support a phase 2 clinical trial of EI-1071, a highly potent Colony-Stimulating Factor-1 Receptor inhibitor. The goal is to reduce the numbers and the associated inflammatory activity of brain microglia in Alzheimer’s patients. This follows the successful completion of a first-in-human phase 1 study in healthy volunteers that was also made possible in part thanks to an earlier Alzheimer’s Association Part the Cloud-Bill Gates Partnership program grant. Read our press release here and the Alzheimer’s Association announcement here